NRX Pharmaceuticals, Inc. (NRXP): Nasdaq/NYSE listing notice — NRx Pharmaceuticals transfers listing to Nasdaq Capital Market effective Jan 19, 2024

NRX Pharmaceuticals, Inc.

Nasdaq approved transfer from Global Market to Capital Market; effective Jan 19, 2024.
Company had previously received extension until April 16, 2024 to regain compliance.
Transfer is a condition of the extension; avoids immediate delisting.
Listing on Capital Market subject to continued compliance with rules.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NRX Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 1, 2024, Nasdaq informed the Company that it had approved the Company’s application to transfer its listing and that the Company’s securities were transferred to The Nasdaq Capital Market at the opening of business on January 19, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: February 2, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Acting General Counsel

View on SEC.gov

Browse all listing & compliance notices →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-010087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.